FDA Issues Complete Response Letter to GlaxoSmithKline for Eurand's EUR-1048
26 déc. 2008 16h00 HE
|
Eurand N.V.
PHILADELPHIA, Dec. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
FDA Issues Complete Response Letter to GlaxoSmithKline for Eurand's EUR-1048
26 déc. 2008 16h00 HE
|
Eurand N.V.
GlaxoSmithKline Responds to Complete Response Letter
PHILADELPHIA, Dec. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a
specialty pharmaceutical company that develops enhanced...
Eurand's Raw Material Supplier Submits Response to FDA for DMF-Related Questions On EUR-1008 (ZENTASE(r))
23 déc. 2008 13h03 HE
|
Eurand N.V.
PHILADELPHIA, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a
specialty pharmaceutical company that develops enhanced pharmaceutical and
biopharmaceutical products based on its...
Eurand's Raw Material Supplier Submits Response to FDA for DMF-Related Questions On EUR-1008 (ZENTASE(r))
23 déc. 2008 12h51 HE
|
Eurand N.V.
PHILADELPHIA, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
Eurand Appoints Dr. Ruth Thieroff-Ekerdt as Chief Medical Officer
20 nov. 2008 11h00 HE
|
Eurand N.V.
PHILADELPHIA, Nov. 20, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
Eurand to Present At Lazard Capital Markets 5th Annual Healthcare Conference
11 nov. 2008 14h11 HE
|
Eurand N.V.
PHILADELPHIA, Nov. 11, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...
Eurand Reports Recent Developments and Third Quarter and Year-to-Date 2008 Financial Results
07 nov. 2008 07h00 HE
|
Eurand N.V.
Highlights:
* Grew third quarter 2008 revenues to EUR 24.6 million ($32.0
million), a 30% increase in constant currency from the third
quarter of 2007;
* Grew year-to-date...
Eurand Announces Conference Call On Third Quarter 2008 Financial Results
09 oct. 2008 12h30 HE
|
Eurand N.V.
AMSTERDAM, The Netherlands, Oct. 9, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and...
Eurand Provides Update On EUR-1008 (ZENTASE)
30 sept. 2008 09h31 HE
|
Eurand N.V.
PHILADELPHIA, Sept. 30, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and...
Eurand to Present At Thomas Weisel Partners Healthcare Conference 2008
26 août 2008 10h37 HE
|
Eurand N.V.
PHILADELPHIA, Aug. 26, 2008 (GLOBE NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its...